Friday, July 22, 2011
Inotek Pharmaceuticals Corp., of Lexington, Mass., completed the first two of three stages of a multiple-dose Phase IIb trial of its eye drop candidate, INO-8875, in patients with glaucoma or ocular hypertension. Based on the achievement of the milestone, Inotek's investors have committed the final tranche of their previous $20 million funding round and have committed an additional $3.7 million to expand the final portion of the ongoing clinical trial by increasing the number of subjects and the duration of treatment in the final phase.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.